Overview

Combination of Rituximab and NK Immunotherapy for B Lymphoma

Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study is the safety and efficacy of Rituximab plus NK immunotherapy to recurrent B lymphoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fuda Cancer Hospital, Guangzhou
Collaborator:
Shenzhen Hank Bioengineering Institute
Treatments:
Rituximab